Illexcor Therapeutics
$14Mtotal raised · 7 rounds on record
$13Mlatest round · Venture round · Apr 2026 · 6 mo ago
$5Mrevenue · 2025 · SEC Form D 0002132799-26-000001
$5.6Mgrants · 5 grants · CORDIS
Funding and backers
Total raised
$14M
7 rounds on record
Latest round
$13M
Venture round · Apr 2026 · 6 mo ago
Team
11-50
employees, estimated range
Grants
$5.6M
5 grants · CORDIS
Revenue
$5M
2025 · SEC Form D 0002132799-26-000001
The money's age
Fresh money
6 months since the last round · not hiring
Momentum
20/100
fresh money
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Apr 15
Raised a round Venture round $13M · SEC Form D
2026
Founded
Mar 24, 2025
New executive Martin Safo, Executive Officer · SEC Form D
Mar 8, 2025
Raised a round Venture round $1M · SEC Form D
Sep 1, 2023
Won a grant $2.4M · CORDIS
Jul 1, 2023
Won a grant $2.4M · CORDIS
Jan 1, 2021
Won a grant $298k · CORDIS
Aug 15, 2020
Won a grant $300k · CORDIS
Mar 1, 2020
Won a grant $300k · CORDIS
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Apr 2026 | $13M | — | SEC Form D |
| Venture round | Mar 2025 | $1M | — | SEC Form D |
| Grant | Sep 2023 | $2.4M | — | CORDIS |
| Grant | Jul 2023 | $2.4M | — | CORDIS |
| Grant | Jan 2021 | $298k | — | CORDIS |
| Grant | Aug 2020 | $300k | — | CORDIS |
| Grant | Mar 2020 | $300k | — | CORDIS |
Registers and programsofficial lists and records that name the company
| Legal entity | Illexcor Therapeutics, Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Timothy LadinExecutive OfficerSEC Form D
Andrew FleischmanExecutive Officer, DirectorSEC Form D
Martin SafoExecutive OfficerSEC Form D
Financials
Est. Annual Revenue
$3M
2025
Total raised
$19.6M
Latest round
Venture - Series Unknown
Funding rounds
7
People
Timothy Ladin
Executive Officer
Andrew Fleischman
Executive Officer, Director
Martin Safo
Executive Officer
Maneka Mirchandaney
Director
Giovanni Mariggi
Director
Ted Love
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
News
Zydus' Zynext Ventures Invests in Illexcor to Advance Sickle Cell Drug India Infoline
Illexcor Therapeutics is a biopharmaceutical company dedicated to the creation of next-gen oral therapies to treat patients living with SCD
Read more
Report
Zynext Ventures invests in Illexcor Therapeutics to advance novel oral therapy for sickle cell disease
Zynext Ventures USA LLC (Zynext Ventures), the venture capital arm of Zydus Lifesciences (Zydus), today announced its investment in Illexcor Therapeutics (Illexcor), a pioneering biopharmaceutical company developing next-generation oral therapies for sick
Read more
Report
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Richmond
United States
HQ
10-50 est. staff